Connect
MJA
MJA

Biosimilars: is interchangeability the proof of the pudding?

Gregory T Moore and Charlotte Keung
Med J Aust 2021; 214 (3): . || doi: 10.5694/mja2.50912
Published online: 15 February 2021

While apparently non‐inferior to originator biologics, other factors need to be considered before switching

Biologic drugs are large monoclonal antibodies or genetically engineered proteins produced by live organisms. With highly specific targets, they have revolutionised the treatment of inflammatory, endocrine, and malignant conditions. However, these drugs are expensive, partly because of the complex and costly manufacturing processes required, partly because long periods of therapy are often needed.

  • Gregory T Moore1,2
  • Charlotte Keung1

  • 1 Monash Health, Melbourne, VIC
  • 2 Monash University, Melbourne, VIC

Correspondence: gregory.moore@monash.edu

Competing interests:

Gregory Moore has received payment for advisory boards from AbbVie, BMS, Chiesi, Emerge, Gilead, Hospira, Janssen, Orphan, MSD, Pfizer, Shire, Takeda; speaker’s fees from AbbVie, Ferring, Janssen, Orphan, Pfizer, Roche, Shire, and Takeda; and research and educational support from AbbVie, Janssen, Pfizer, Shire, and Takeda.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.